Methylprednisolone

DRUG INFORMATION

  ADULT
    - The doses in the following table are given as a general guide: Size of Joint
      Examples Range of Dosage Large Knees Ankles Shoulders 20 to 80 mg Medium Elbows
      Wrists 10 to 40 mg Small Metacarpophalangeal Interphalangeal Sternoclavicular
      Acromioclavicular 4 to 10 mg Procedure: It is recommended that the anatomy of the
      joint involved be reviewed before attempting intra-articular injection.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'dosage and administration', retrieved 2026-08-29
    - The dose in the treatment of the various conditions of the tendinous or bursal
      structures listed above varies with the condition being treated and ranges from 4
      to 30 mg.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'dosage and administration', retrieved 2026-08-29
    - It may be necessary to distribute doses ranging from 20 to 40 mg by repeated local
      injections in the case of large lesions.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'dosage and administration', retrieved 2026-08-29

  CHILD
    - The efficacy and safety of corticosteroids in the pediatric population are based
      on the well-established course of effect of corticosteroids which is similar in
      pediatric and adult populations. Published studies provide evidence of efficacy
      and safety in pediatric patients for the treatment of nephritic syndrome (patients
      >2 years of age) and aggressive lymphomas and leukemias (patients >1 month of
      age).
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'pediatric use', retrieved 2026-08-29
    - Because of possible physical incompatibilities, methylprednisolone acetate
      injectable suspension, USP should not be diluted or mixed with other solutions.
      The initial dosage of parenterally administered methylprednisolone acetate
      injectable suspension, USP will vary from 4 to 120 mg, depending on the specific
      disease entity being treated.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for methylprednisolone
      (Methylprednisolone Acetate), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for methylprednisolone
      (Methylprednisolone Acetate), retrieved 2026-08-29

  PREGNANCY
    - Teratogenic Effects Corticosteroids have been shown to be teratogenic in many
      species when given in doses equivalent to the human dose.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'pregnancy', retrieved 2026-08-29
    - Animal studies in which corticosteroids have been given to pregnant mice, rats,
      and rabbits have yielded an increased incidence of cleft palate in the offspring.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'pregnancy', retrieved 2026-08-29
    - There are no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Systemically administered corticosteroids appear in human milk and could suppress
      growth, interfere with endogenous corticosteroid production, or cause other
      untoward effects.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'nursing mothers', retrieved 2026-08-29
    - Because of the potential for serious adverse reactions in nursing infants from
      corticosteroids, a decision should be made whether to discontinue nursing or
      discontinue the drug, taking into account the importance of the drug to the
      mother.
      Source: US FDA label for methylprednisolone (Methylprednisolone Acetate), section
      'nursing mothers', retrieved 2026-08-29